Artelo Biosciences, Inc. (ARTL)
USD 0.96
(-7.69%)
USD 0.96
(-7.69%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8 Million | -6.14 Million | -4.34 Million | -2.79 Million | -1.61 Million | -216.82 Thousand |
| Net Income | -10.08 Million | -7.43 Million | -4.65 Million | -2.17 Million | -2.34 Million | -234.88 Thousand |
| Depreciation & Amortization | - | - | 500.00 | 510.00 | 282.00 | 600.00 |
| Deferred income taxes | - | - | - | -1 Million | - | -600.00 |
| Stock-based compensation | 2.45 Million | 1.53 Million | 377.76 Thousand | 425.11 Thousand | 290 Thousand | 3332.00 |
| Change in working capital | -172 Thousand | -242 Thousand | -41.28 Thousand | -140.02 Thousand | 443.18 Thousand | 14.13 Thousand |
| Other non-cash items | -211 Thousand | 7000.00 | -29.5 Thousand | 100 Thousand | - | 600.00 |
| Investing Cash Flow | 2.95 Million | -3.43 Million | - | -1.5 Million | -845.00 | - |
| Investments in PPE | - | - | - | -1.5 Million | -845.00 | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -13.22 Million | -3.43 Million | - | - | - | - |
| Sales/Maturities of investments | 16.18 Million | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | 14.11 Million | 1.98 Million | 8.37 Million | 1.38 Million | 785.34 Thousand |
| Debt repayment | - | - | - | - | - | -30 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -108.00 | - | - | - |
| Common Stock Issuance | - | 8.1 Million | 1.97 Million | 8.37 Million | 1.38 Million | 772.68 Thousand |
| Other Financing Activities | - | 6 Million | 3153.00 | 1048.00 | 1838.00 | 42.66 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 23 Thousand | -3000.00 | 127.97 Thousand | -180.4 Thousand | 500.69 Thousand | 15.63 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -195 Thousand | -239 Thousand | -169.26 Thousand | 40.38 Thousand | -57.51 Thousand | -1500.00 |
| Cash at beginning of period | 12.16 Million | 2.14 Million | 4.42 Million | 337.42 Thousand | 572.77 Thousand | 3590.00 |
| Cash at end of period | 6.88 Million | 6.62 Million | 2.14 Million | 4.42 Million | 337.42 Thousand | 572.77 Thousand |
| Capital Expenditure | - | - | - | -1.5 Million | -845.00 | - |
| Effect of forex changes on cash | -224 Thousand | -45 Thousand | 84.75 Thousand | 2478.00 | -12.93 Thousand | 657.00 |
| Net cash flow / Change in cash | -5.27 Million | 4.48 Million | -2.28 Million | 4.08 Million | -235.35 Thousand | 569.18 Thousand |
| Free Cash Flow | -8 Million | -6.14 Million | -4.34 Million | -4.29 Million | -1.61 Million | -216.82 Thousand |
| Breakdown | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 | 2022 Q3 | 2022 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.59 Million | -2.16 Million | -10.08 Million | -3.33 Million | -2.33 Million | -2.44 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 225 Thousand | 354 Thousand | 2.45 Million | 608 Thousand | 607 Thousand | 619 Thousand |
| Change in working capital | -62 Thousand | -248 Thousand | -172 Thousand | 575 Thousand | 97 Thousand | -113 Thousand |
| Other non-cash items | -187 Thousand | -124 Thousand | -211 Thousand | -137 Thousand | -70 Thousand | -23 Thousand |
| Investing Cash Flow | 399 Thousand | 2.19 Million | 2.95 Million | 1.79 Million | -3.08 Million | 3.98 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -2.35 Million | -5.8 Million | -13.22 Million | -2.18 Million | -7.85 Million | -740 Thousand |
| Sales/Maturities of investments | 2.75 Million | 8 Million | 16.18 Million | 3.97 Million | 4.77 Million | 4.72 Million |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -1.25 Million | - | - | 134 Thousand | - | -134 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -231 Thousand | -180 Thousand | 23 Thousand | 579 Thousand | -42 Thousand | -377 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 169 Thousand | -68 Thousand | -195 Thousand | -4000.00 | 139 Thousand | 264 Thousand |
| Cash at beginning of period | 6.91 Million | 6.88 Million | 12.16 Million | 7.13 Million | 12.12 Million | 10.35 Million |
| Cash at end of period | 5.71 Million | 6.91 Million | 6.88 Million | 6.88 Million | 7.13 Million | 12.12 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | 27 Thousand | 15 Thousand | -224 Thousand | 115 Thousand | -210 Thousand | -113 Thousand |
| Net cash flow / Change in cash | -1.19 Million | 28 Thousand | -5.27 Million | -248 Thousand | -4.98 Million | 1.77 Million |
| Free Cash Flow | -1.62 Million | -2.18 Million | -8 Million | -2.29 Million | -1.69 Million | -1.96 Million |
STGN
SLBEN
FGFL
IDDWF
461030
COP